IPO Journey
Avalyn Pharma Inc.
IPO Date: April 30, 2026 · 4 filings tracked
Final Offer Terms
Ticker
AVLN
Exchange
Nasdaq Global Select Market
Offer Price
$18.00
Shares Offered
16,666,667
Estimated Proceeds
$300.0M
Underwriters
Led by Morgan Stanley, Jefferies
Evercore ISIGuggenheim Securities
Filing Timeline
1
S-1
April 8, 2026
- Targets rare, life-threatening lung diseases like pulmonary fibrosis
- Innovative inhaled delivery system aims to reduce systemic side effects
2
S-1/A
April 23, 2026
- Targets a $4 billion market for oral lung disease therapies.
- Proprietary eFlow® nebulizer technology aims to reduce side effects.
Changes from previous filing
- ▸ Expected offer range: $16.0 – $18.0 per share
- ▸ Shares offered: 11,800,000
- ▸ Estimated proceeds: $188M
3
S-1/A
April 29, 2026
- Targets severe lung diseases with a novel inhaled delivery platform
- Reformulates proven drugs to minimize systemic side effects
Changes from previous filing
- ▸ Shares offered: 16,666,667
- ▸ Estimated proceeds: $266M
424B4
Final Pricing
April 30, 2026
- Innovative drug-device combination targeting rare respiratory diseases
- Proprietary high-efficiency nebulizer technology improves drug delivery
Changes from previous filing
- ▸ Exchange: Nasdaq Global Select Market
- ▸ Price range removed
- ▸ Final offer price: $18.0 per share
- ▸ Estimated proceeds: $300M
- ▸ Underwriters: Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.